STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   CURTIS GEOFFREY M.
   (Last) (First) (Middle)
   C/O HORIZON THERAPEUTICS PLC
   CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
   DUBLIN L2 4
   (Street) (City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
   Horizon Therapeutics Public Ltd Co [HZNP]

3. Date of Earliest Transaction (Month/Day/Year)
   01/21/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   01/21/2020

5. Relationship of Reporting Person(s) to Issuer
   (Check all applicable)
   Director
   X 10% Owner
   Officer (give title below)
   EVP, Corporate Affairs, CCO

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)
   Ordinary Shares

2. Transaction Date (Month/Day/Year)
   01/21/2020

3. Transaction Code (Instr. 3)
   A

4. Securities Acquired (A) or Disposed Of (D) (Instr. 4)
   A

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
   3,998

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
   D

7. Nature of Indirect Beneficial Ownership (Instr. 4)
   By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)
   Restricted Stock Units (RSU)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)
   01/21/2020

4. Transaction Code (Instr. 3)
   A

5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 4)
   7,998

6. Date Exercisable and Expiration Date (Month/Day/Year)
   (i) Ordinary Shares

7. Title and Amount or Number of Securities Underlying Derivative Security (Instr. 3 and 4)
   Ordinary Shares

8. Price of derivative Security (Instr. 5)
   $0.00

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
   7,998

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
1. On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022.
2. Each PSU represents a contingent right to receive one ordinary share of the Issuer.

Remarks:

/s/ Miles W. McHugh
Attorney-in-Fact 01/23/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see instruction 4 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.